eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium

Rhea-AI Summary

eXoZymes (NASDAQ:EXOZ) announced that CCO Damien Perriman will present a solution for scaling production of NCT at the MISTA Symposium Healthspan on March 18, 2026 in San Francisco. The talk will cover NCT's role in metabolic health and cell-free enzyme production using the company's AI-designed exozyme platform.

The company says its cell-free enzyme cascades aim to enable scalable supply of a rare plant-derived molecule for nutraceutical and pharmaceutical applications.

News Market Reaction – EXOZ

+1.25%

1 alert

+1.25% News Effect

On the day this news was published, EXOZ gained 1.25%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Shelf registration size: $50,000,000 MISTA presentation date: March 18, 2026

2 metrics

Shelf registration size $50,000,000 New S-3 shelf filed 2026-01-16 for mixed securities offerings

MISTA presentation date March 18, 2026 Scheduled symposium presentation on NCT scaling and metabolic health

Market Reality Check

Price: $7.13 Vol: Volume 1,641 is below the...

low vol

$7.13 Last Close

Volume Volume 1,641 is below the 20-day average of 3,335, suggesting limited pre-event positioning. low

Technical Shares at $7.30 are trading below the 200-day MA of $11.84 and sit close to the 52-week low of $7.08.

Peers on Argus

EXOZ was flat while biotech peers were mixed: ADAG up 21.16%, VTGN up 7.29%, ARM...

1 Up

EXOZ was flat while biotech peers were mixed: ADAG up 21.16%, VTGN up 7.29%, ARMP down 4.01%, TCRX down 0.86%, FATE down 4.65%. The momentum scanner separately flagged ARMP up about 3.10%, but EXOZ showed no pre-news move, pointing to stock-specific rather than sector-wide positioning.

Historical Context

5 past events · Latest: Feb 10 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 10	Brand and strategy refresh	Positive	-3.6%	Refreshed brand and sharper focus on pharma and high-value nutraceuticals.
Jan 29	NCT pilot run metrics	Positive	+2.1%	Reported high-conversion, high-yield NCT pilot run with pharma-grade purity.
Dec 11	NCT 100× scale-up	Positive	-9.8%	Announced successful 100× NCT scale-up and strong feedstock conversion.
Nov 13	Q3 2025 update	Negative	-7.0%	Quarterly update outlining net losses, higher expenses, and limited cash runway.
Nov 13	Leadership changes	Neutral	-7.0%	Appointed co-founder as CSO and named new chief of staff.

Pattern Detected

Operational and branding/NCT updates have produced mixed reactions, with several positive-sounding milestones followed by negative price moves, indicating uneven investor confidence.

Recent Company History

Over the past six months, EXOZ has focused on its NCT program and platform positioning. On Dec 11, 2025, it reported a 100× NCT scale-up using its exozyme platform, yet shares fell about 9.81%. A Q3 2025 update on Nov 13, 2025 highlighted ongoing losses and limited cash runway, and the stock declined roughly 6.95%. Early 2026 updates, including strong NCT pilot-run metrics on Jan 29, 2026 and a refreshed brand on Feb 10, 2026, drew modest or negative reactions. Today’s symposium-focused announcement fits this pattern of NCT-centric, platform-leverage messaging.

Regulatory & Risk Context

Active S-3 Shelf · $50,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-16

$50,000,000 registered capacity

An effective S-3 shelf filed on 2026-01-16 registers up to $50,000,000 of mixed securities, giving EXOZ flexibility to raise capital over time. Net proceeds are earmarked for working capital, R&D, regulatory and clinical activities, capital expenditures, and potential acquisitions, which could result in dilution to existing stockholders when utilized.

Market Pulse Summary

This announcement spotlights EXOZ’s NCT program and platform by featuring its CCO at the March 18, 2...

Analysis

This announcement spotlights EXOZ’s NCT program and platform by featuring its CCO at the March 18, 2026 MISTA Healthspan symposium, emphasizing metabolic health and cell-free enzyme engineering. It builds on prior NCT scale-up and pilot-run updates without adding new financial data. Investors may track how the company converts this visibility into partnerships or product pathways, while also monitoring its use of the $50,000,000 shelf and future disclosures on commercialization plans.

Key Terms

nutraceuticals, pharmaceutical applications, metabolic health, cell-free enzyme engineering, +1 more

5 terms

nutraceuticals medical

"transforms abundant feedstock into valuable nutraceuticals and novel medicines"

Nutraceuticals are products made from food sources that claim to provide extra health benefits beyond basic nutrition, such as dietary supplements, fortified foods, and concentrated extracts—think vitamin pills or functional foods marketed for specific wellness effects. They matter to investors because demand, regulatory rules, and scientific evidence strongly influence sales, pricing and risk: solid clinical support and clear regulations can boost a product’s market value, while weak evidence or regulatory action can cut revenues quickly.

pharmaceutical applications medical

"NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications."

Pharmaceutical applications are the specific medical uses for a drug or compound—what conditions it treats, how it’s delivered, and the role it plays in care—like choosing the right tool for a particular job. Investors care because each application determines how big the potential market is, what regulatory hurdles and safety checks are required, and how reliably the product can generate sales, much like a kitchen appliance’s value depends on which tasks it can perform well.

metabolic health medical

"The presentation will focus on NCT's potential role in metabolic health and its emerging relevance"

Metabolic health describes how well a person’s body turns food into energy and keeps blood sugar, cholesterol, blood pressure, weight and inflammation in healthy ranges. It matters to investors because poor metabolic health drives demand for drugs, medical devices, diagnostics and wellness services, raises healthcare costs and affects workforce productivity—think of it as the engine efficiency of a population that influences market size and future earnings.

cell-free enzyme engineering technical

"advances in cell-free enzyme engineering are making it possible to bring this rare natural compound"

Cell-free enzyme engineering is the practice of building, testing and improving enzymes outside of living cells by mixing genetic material, proteins and chemical ingredients in a controlled, test‑tube system. For investors it matters because this approach lets companies iterate and validate enzyme designs far faster and cheaper than cell-based methods—like tuning an engine on a workbench instead of inside a car—reducing development time, technical risk and costs for biotech, industrial chemistry and diagnostic products.

enzyme cascades technical

"using AI-designed enzyme cascades operating outside living cells."

Enzyme cascades are chains of chemical steps inside cells where one enzyme’s action triggers the next, creating a fast, amplified biological response—like a row of falling dominoes where the first push sets off many. Investors care because these chains are often drug targets, diagnostic signals, or manufacturing steps: disrupting or harnessing a cascade can change a therapy’s effectiveness, safety profile, or a test’s sensitivity, which affects a biotech’s commercial value.

AI-generated analysis. Not financial advice.

LOS ANGELES, CA / ACCESS Newswire / March 12, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals and novel medicines - announced that Perriman will present a solution for scaling production of NCT, a naturally occurring small molecule currently being developed by eXoZymes for both nutraceutical and pharmaceutical applications.

The presentation will focus on NCT's potential role in metabolic health and its emerging relevance in the rapidly evolving landscape of food, supplements, and longevity-focused wellness solutions.

The March 18, 2026, MISTA Symposium Healthspan event in San Francisco brings together leaders from the food, nutrition, and health industries to explore how scientific advances can support healthier aging and improved metabolic resilience through nutrition and biotechnology.

"When it comes to health, a lot of people feel frustrated because they're trying - but nothing seems to work. They feel trapped between conflicting advice and solutions that are difficult to sustain. But now there's hope - what makes NCT so exciting is that it focuses on the underlying problem: how the body converts fuel into energy. By addressing that fundamental process, we believe it could represent a meaningful new approach to metabolic health," states Damien Perriman, Chief Commercial Officer of eXoZymes, and adds. "We're excited to share how advances in cell-free enzyme engineering are making it possible to bring this rare natural compound into scalable production and explore its potential across nutrition and medicine."

NCT was discovered in nature as a plant-derived molecule that has attracted growing attention for its potential metabolic benefits. Historically, its rarity in nature has limited broader development and commercial exploration. By leveraging its proprietary exozyme platform, eXoZymes is working to enable efficient production of NCT and related compounds using AI-designed enzyme cascades operating outside living cells.

The company believes this approach could unlock scalable supply of molecules that were previously impractical to produce, opening new opportunities across nutraceutical, pharmaceutical, and specialty ingredient markets.

About eXoZymes
Founded in 2019, the company has developed a biomanufacturing platform that - as a historic first - offers the tools and insights to design, engineer, control and optimize nature's own natural processes to produce highly valuable natural products, via a commercially scalable, sustainable, and abundant alternative: exozymes.

Exozymes are advanced enzymes enhanced through bioengineering and AI to thrive in a bioreactor without using living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions that transform abundant feedstock into valuable nutraceuticals and novel medicines.

By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the next generation of biomanufacturing.

While the company, eXoZymes Inc., has introduced "exozymes" as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption for this next generation of biomanufacturing that eXoZymes aims to pioneer and be the market leader of.

Learn more at exozymes.com

eXoZymes Safe Harbor
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate," "strategy," "future," "likely," "potential," or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Actual results could differ materially for a variety of reasons. You should carefully consider the risks and uncertainties described in the "Risk Factors" section of eXoZymes' quarterly reports on Form 10-Q, annual reports on Form 10-K, and other documents filed by eXoZymes from time to time by the company with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and eXoZymes assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. eXoZymes does not give any assurance that it will achieve its expectations.

eXoZymes contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com

https://www.linkedin.com/company/exozymes
https://x.com/exozymes
https://www.youtube.com/@exozymes

SOURCE: eXoZymes Inc.

View the original press release on ACCESS Newswire

FAQ

What will eXoZymes (EXOZ) present about NCT at the MISTA Symposium on March 18, 2026?

They will present a solution for scaling production of NCT using cell-free, AI-designed enzyme cascades. According to the company, the presentation focuses on NCT's metabolic health potential and how exozyme technology can enable scalable supply for nutraceutical and pharmaceutical uses.

How does eXoZymes plan to produce NCT at scale as described by EXOZ on March 12, 2026?

By using proprietary cell-free enzyme cascades designed with AI to convert feedstock into NCT efficiently. According to the company, this exozyme platform operates outside living cells to address rarity and enable larger, more practical production volumes for industry use.

What is NCT and why is eXoZymes (EXOZ) highlighting it at the MISTA Healthspan event?

NCT is a rare, plant-derived small molecule of interest for metabolic health and longevity-focused wellness. According to the company, NCT's scarcity has limited development, and scalable production could open nutraceutical and pharmaceutical opportunities if efficacy and safety are established.

When and where will Damien Perriman of eXoZymes present the NCT solution at MISTA 2026?

Damien Perriman will present on March 18, 2026 at the MISTA Symposium Healthspan in San Francisco. According to the company, the event gathers leaders in food, nutrition, and health to discuss scientific advances supporting healthier aging and metabolic resilience.

What potential markets did eXoZymes (EXOZ) cite for NCT during the March 12, 2026 announcement?

They cited nutraceutical, pharmaceutical, and specialty ingredient markets as potential applications for NCT. According to the company, scalable production via their exozyme platform could make previously impractical molecules commercially viable across these sectors.